scholarly journals Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report

2021 ◽  
Vol 21 (2) ◽  
pp. 177-180
Author(s):  
Sang Youn Hwang ◽  
Sun Mi Lee ◽  
Jeong Woo Lim ◽  
Gi Jung Jeon ◽  
Hye Won Lee
Keyword(s):  
Lymph Node ◽  
Combination Therapy ◽  
Systemic Treatment ◽  
Real Life ◽  
Complete Response ◽  
Phase Iii ◽  
First Line ◽  
Life Data ◽  
Node Metastasis ◽  
Real Life Data

Sorafenib is the oldest first line systemic treatment in patients with advanced hepatocellularcarcinoma (HCC) and has been used exclusively for nearly 10 years. The superiority ofadministering a combination of atezolizumab plus bevacizumab (AteBeva) compared tosorafenib as first line systemic treatment for unresectable HCC was recently proven duringthe IMbrave150 Phase III randomized trial. While clinicians can expect improved responsesand treatment outcomes due to the good results of the IMbrave 150 trial, they must alsoconsider that atezolizumab can cause various immune-related adverse events (IrAEs). Basedon the above suggestions, we herein present a case of HCC with lymph node metastasiswho achieved complete remission following treatment with AteBeva and developed an IrAE(adrenal insufficiency). Further study of real-life data regarding combination therapy withAteBeva is needed to manage patients with advanced HCC.

scholarly journals Advantages of Tailored Isotretinoin Treatment in Moderate to Severe Acne: Real-Life Data

2021 ◽  
Vol 12 ◽  
Author(s):  
Nevena Skroza ◽  
Ersilia Tolino ◽  
Veronica Balduzzi ◽  
Nicoletta Bernardini ◽  
Alessandra Mambrin ◽  
...  
Keyword(s):  
Dose Adjustment ◽  
Systemic Treatment ◽  
Real Life ◽  
Efficacy And Safety ◽  
Single Center ◽  
Severe Acne ◽  
Life Data ◽  
Real Life Data ◽  
Single Center Study ◽  
Center Study

This retrospective single-center study analyzes the efficacy and safety of isotretinoin for the treatment of moderate to severe acne in real-life clinical practice, particularly with regard to acne severity, isotretinoin cumulative dosage, and patients’ gender. The results suggest the opportunity of an early isotretinoin systemic treatment in patients affected by moderate acne and emphasize the importance of an appropriate dose adjustment in order to minimize adverse events.

Real-life data of niraparib maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 5560-5560
Author(s):  
Bente Vilming ◽  
Jørgen Fallås-Dahl ◽  
Anne-Gry Bentzen ◽  
Vibeke Anett Ingebrigtsen ◽  
Elisabeth Berge Nilsen ◽  
...  
Keyword(s):  
Adverse Events ◽  
Maintenance Treatment ◽  
Real Life ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Life Data ◽  
Platinum Sensitive ◽  
Real Life Data ◽  
Individualized Dosing ◽  
Grade 3

5560 Background: PARP (poly adenosine diphosphate [ADP]–ribose polymerase) inhibitors are the new standard for maintenance treatment in platinum sensitive recurrent ovarian cancer (PSROC), independent of germline (g-BRCA) or somatic BRCA mutation status. Real-life data after the introduction of new anti-neoplastic agents are needed to evaluate whether the benefit observed in phase III trials can be translated into clinical practice. The aim of this study was to provide real-life data on efficacy and safety of niraparib in non-gBRCA PSROC. Methods: This retrospective multi-center cohort study included patients with PSROC who were enrolled in a national individual patient access program in Norway. Efficacy and safety data were collected from the patients´ electronic medical records. The primary outcome was time from start of niraparib treatment to first subsequent treatment (TFST). Secondary endpoints included prevalence of dose interruption and -reduction, as well as adverse events. Results: The study included 106 patients with median age of 64 years (range 38-81). After median follow up of 15.3 months (95% CI 12.1-18.5), 71 patients (67%) had progressed, 64 (60%) had started a new line of treatment, and 25 (24%) had died. 25 (24%) patients were still receiving niraparib. Median duration of niraparib treatment was 7.6 months (0.4 to 27.3 months). Median TFST was 11.7 months (95% CI 9.2 -14.2). Patients with elevated CA125 after chemotherapy prior to start of niraparib had shorter progression-free survival (PFS) compared to patients with complete serological response (6.5 months (95% CI 5.7 – 7.3) vs 12 months (95% CI 6.2 – 17.9, (p < 0.001)). Grade 3-4 hematologic and non-hematologic events occurred in 25% and 17% of the patients, respectively. The most common grade 3/4 hematologic events were anemia (15%), thrombocytopenia (11%) and neutropenia (8%). Adverse events led to dose interruption in 38% and dose reduction in 44% of the patients. Patients with individualized dosing based on baseline weight and platelet counts had fewer dose reductions (p < 0.001) and -interruptions (p = 0.042) than patients whose dose was not adjusted to those baseline values. Conclusions: In a real-life setting, niraparib maintenance treatment in patients with non-gBRCA PSROC showed efficacy comparable with the published phase III data and an acceptable safety profile. Individualized dosing at start of treatment minimized adverse events. The prolonged PFS in patients with CA125 normalization after last chemotherapy, suggests that these patients in particular benefit from maintenance treatment but warrants confirmation in a larger sample.[Table: see text]

scholarly journals Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases

2021 ◽  
Vol 156 ◽  
pp. 149-163
Author(s):  
Marie-Luise Hilbers ◽  
Florentia Dimitriou ◽  
Peter Lau ◽  
Prachi Bhave ◽  
Grant A. McArthur ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Brain Metastases ◽  
Immune Checkpoint ◽  
Real Life ◽  
Checkpoint Inhibition ◽  
Immune Checkpoint Inhibition ◽  
First Line ◽  
Life Data ◽  
Real Life Data ◽  
Melanoma Brain Metastases

scholarly journals Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry

2016 ◽  
Vol 68 (4) ◽  
pp. 432-439 ◽  
Author(s):  
Ennio Giulio Favalli ◽  
Francesca Pregnolato ◽  
Martina Biggioggero ◽  
Andrea Becciolini ◽  
Alessandra Emiliana Penatti ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Retention Rate ◽  
Real Life ◽  
Tumor Necrosis Factor Inhibitors ◽  
First Line ◽  
Life Data ◽  
Real Life Data ◽  
Necrosis Factor

scholarly journals Antifungal Combination Therapy in Children with Cancer—A 4-Year Analysis of Real-Life Data of Two Major Pediatric Cancer Centers

2021 ◽  
Vol 7 (8) ◽  
pp. 604
Author(s):  
Stefan Schöning ◽  
Konrad Bochennek ◽  
Kathrin Gordon ◽  
Andreas H. Groll ◽  
Thomas Lehrnbecher
Keyword(s):  
Combination Therapy ◽  
Pediatric Cancer ◽  
Hematopoietic Cell Transplantation ◽  
Real Life ◽  
Invasive Fungal Disease ◽  
Fungal Disease ◽  
Clinical Deterioration ◽  
Cancer Centers ◽  
Life Data ◽  
Real Life Data

Clinical data on antifungal combination therapy are limited, in particular in the pediatric setting. We analyzed real-life data collected in two major pediatric cancer centers over a period of 4 years. Patients were identified in an observational study on children with acute leukemia and lymphoma or undergoing hematopoietic cell transplantation. Out of 438 patients, 19 patients received 21 episodes of antifungal combination therapy. Therapy was mostly started for sepsis (n = 5) or clinical deterioration with pulmonary infiltrates (n = 10), and less often for periorbital swelling with suspected mold infection (n = 2), clinical deterioration and new skin lesions, secondary antifungal prophylaxis, a persistently elevated galactomannan index, or as pre-emptive treatment (n = 1 each). Diagnostics revealed proven, probable, and possible invasive fungal disease in two, seven and four episodes, respectively. Most regimens included caspofungin (n = 19), and treatment was initiated as first line therapy in 10 episodes. The median duration was 13 days (4–46 days). Nine of the 13 patients with proven, probable, or possible invasive fungal disease survived, which was comparable to patients receiving antifungal monotherapy. Our analysis demonstrates that combination therapy has mainly been prescribed in selected immunocompromised patients with clinical deterioration due to suspected invasive fungal disease or those with sepsis, and is well tolerated. Future studies need to better characterize clinical settings in which patients may benefit from antifungal combination therapy.

VICTOR: Vinflunine (Vin) in advanced metastatic transitional cell carcinoma of the urothelium (TCCU)—A retrospective analysis of use of Vin in multicenter, real life setting as second-line chemotherapy (ChT) through free-of charge-programme (FOCP) for patients (pts) in the UK.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 352-352 ◽  
Author(s):  
Syed A. Hussain ◽  
Jawaher Ansari ◽  
Robert Anthony Huddart ◽  
James Wylie ◽  
Maria Vilarino-Varela ◽  
...  
Keyword(s):  
Randomised Trial ◽  
Transitional Cell ◽  
Real Life ◽  
Phase Iii ◽  
Prognostic Indicators ◽  
Cancer Drug ◽  
Second Line ◽  
Life Data ◽  
Real Life Data ◽  
Real Life Setting

352 Background: There is no standard of care currently in UK for second line ChT for pts with advanced TCC. Vin is approved for TCCU for pts who have failed a platinum-based regimen and is now the standard ChT in 2nd line in Europe based on large phase III randomised trial data showing 2.6 months survival advantage. ESMO guidelines recommended it as the only option for pts in the 2nd line setting. Vin is not currently available in NHS practice in UK as it is not on the approved list of drugs on cancer drug fund. Methods: Data are collected retrospectively on pts who received Vin as a 2nd line treatment through FOCP. The dose of Vin was 240-320 mg/m2 every 3 weeks. The aim was to document the toxicity, radiological RR and OS for pts treated with Vin in real life setting within the FOCP. Results: At the time of analysis data from 37 pts from 6 sites were available. Median pts age was 64 years(range: 57-69), 24m; 13 f. All pts had advanced metastatic TCC. 9 pts had bone or liver mets, 3 pts had PS 2 and 5 pts had HB <10, all known poor prognostic indicators in palliative ChT setting. Total of 179 cycles have been delivered (median 3 ; mean 5; range1-16). Grade 3 / 4 toxicity: Anaemia 2/179, Neutropenia 2/179, Neutropenic infection 2/179, Constipation 4/179, Fatigue 3/179. Grade 2 toxicity; Anaemia 5/179, Neutropenia 13/179, Thrombocytopenia 2/179, Febrile infection 1/179, Constipation 9/179, Fatigue 20/179, Abdominal pain 2/179, Vomiting 8/179. 30 pts were evaluable for response. 11 pts had PR, 6 had SD, 13 had PD and 7 were not evaluable. Partial RR was 30 % with ITT and 37% for evaluable pts. Median OS was 9.5 (95% CI; 5.9- 16.9) months. Conclusions: Real life data showing a median OS of 9.5 m by ITT for all pts are encouraging and consistent with real life data from Europe (Spanish, German and French) presented at ESMO 2013. Toxicity has further improved with the use of prophylactic laxatives and oral antibiotics.

Sign in / Sign up

Export Citation Format

Share Document